Q32 Bio (QTTB) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Initiated Coverage | Outperform | $40.00 | Oct 12, 2026 |
| Jefferies | Initiated Coverage | Buy | $29.00 | Sep 28, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $34.00 | Aug 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $36.00 from $13.00 | Jul 28, 2026 |
| Oppenheimer | Maintained | Outperform | $40.00 from $20.00 | Jul 13, 2026 |
| Wells Fargo | Upgraded | Equal-Weight → Overweight | $66.00 | Jul 13, 2026 |
| Mizuho | Initiated Coverage | Outperform | $14.00 | May 22, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | May 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 | May 5, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $13.00 | Feb 25, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $15.00 from $16.00 | Mar 12, 2025 |
| Piper Sandler | Downgraded | Overweight → Neutral | $4.00 from $20.00 | Feb 11, 2025 |
| BMO Capital | Downgraded | Outperform → Market Perform | $3.00 from $22.00 | Feb 11, 2025 |
| Guggenheim | Downgraded | Buy → Neutral | — | Dec 12, 2024 |
| BMO Capital | Maintained | Outperform | $22.00 from $64.00 | Dec 12, 2024 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $9.00 from $68.00 | Dec 11, 2024 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $16.00 from $95.00 | Dec 11, 2024 |
| Piper Sandler | Maintained | Overweight | $20.00 from $85.00 | Dec 11, 2024 |
| Oppenheimer | Maintained | Outperform | $20.00 from $80.00 | Dec 11, 2024 |
| Raymond James | Downgraded | Strong Buy → Outperform | $22.00 from $90.00 | Dec 11, 2024 |
Frequently asked questions
What is the price target for QTTB stock?
The average 12-month analyst price target for Q32 Bio (QTTB) is $34.75, with a high estimate of $40.00 and a low of $29.00, across 4 analysts.
Is QTTB a buy, sell, or hold?
Analysts covering Q32 Bio currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for QTTB?
The average price target of $34.75 implies 331.14% upside from the last price of $8.06.
What is the latest analyst rating on QTTB?
On Oct 12, 2026, Leerink Partners initiated coverage of Q32 Bio at Outperform with a price target of $40.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.